BaladoCritique – club de lecture médical | médecine interne | EBM
BaladoCritique - club de lecture médical
Claim This Podcastby Dr Luc Lanthier et collaborateurs
5.0(8 reviews)
68 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇨🇦
Podcast Overview
BaladoCritique – club de lecture médical | médecine interne | EBM
Language
🇫🇷
Publishing Since
11/19/2017
1 verified contact email on file for BaladoCritique - club de lecture médical
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 20, 2026
BC 078 – Traitement intensif ciblant le cholestérol-LDL dans la maladie cardiovasculaire athérosclérotique (étude Ez-PAVE)
<p><span style="font-weight: 400;">Dans cette 78</span><span style="font-weight: 400;">e</span><span style="font-weight: 400;"> baladodiffusion, les Drs Luc Lanthier et Pierre-Nicolas Perron discutent de traitement intensif de la dyslipidémie, en plus de réviser la littérature médicale d’avril 2026.</span></p> <p> </p> <p><span style="font-weight: 400;">Quiz clinique (1 min51), présentation principale (2 min 23), critique (16 min 30), retour sur le cas clinique (22 min 25), autres articles (24 min 32), réponse au quiz clinique (27 min 32).</span></p> <p> </p> <h2><b>Référence principale :</b></h2> <p> </p> <p><span style="font-weight: 400;">Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, et al; Ez-PAVE Investigators. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med. 2026;394(14):1365-1375. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41910315/"><span style="font-weight: 400;">41910315</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Articles associés : </b></h3> <p> </p> <p><span style="font-weight: 400;">Probstfield JL, Branch KRH. Paving the Road toward Targeted Lipid Lowering. N Engl J Med. 2026 Apr 9;394(14):1443-1444. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41910324/"><span style="font-weight: 400;">41910324</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40878289/"><span style="font-weight: 400;">40878289</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al; VESALIUS-CV Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026;335(16):1400-1407. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41903215/"><span style="font-weight: 400;">41903215</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/15007110/"><span style="font-weight: 400;">15007110</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/15755765/"><span style="font-weight: 400;">15755765</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/26039521/"><span style="font-weight: 400;">26039521</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/28304224/"><span style="font-weight: 400;">28304224</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/30403574/"><span style="font-weight: 400;">30403574</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Autres articles d’intérêt récent : </b></h3> <p> </p> <p><span style="font-weight: 400;">Landmesser U, Skurk C, Kirchhof P, Lewalter T, Hartung J, Rroku A, et al; CLOSURE-AF Trial Investigators. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. N Engl J Med. 2026;394(13):1270-1280. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41849741/"><span style="font-weight: 400;">41849741</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Choi KH, Kang D, Kim W, Doh JH, Kim J, Park YH, et al; SMART-DECISION Investigators. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. 2026;394(13):1302-1312. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41910427/"><span style="font-weight: 400;">41910427</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, et al; OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026;394(15):1467-1479. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41985132/"><span style="font-weight: 400;">41985132</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, et al; PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. N Engl J Med. 2026;394(16):1583-1594. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/42019019/"><span style="font-weight: 400;">42019019</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Guides de pratique : </b></h3> <p> </p> <p><span style="font-weight: 400;">Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41869847/"><span style="font-weight: 400;">41869847</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41824552/"><span style="font-weight: 400;">41824552</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Références du quiz clinique :</b></h3> <p> </p> <p><span style="font-weight: 400;">Öberg J, Buchwald P, Nilsson A, Nilson B, Inghammar M. Risk and prognosis of colorectal cancer following bacteraemia with </span><i><span style="font-weight: 400;">Streptococcus bovis</span></i><span style="font-weight: 400;">–</span><i><span style="font-weight: 400;">Streptococcus equinus</span></i><span style="font-weight: 400;"> complex: A Swedish nationwide retrospective cohort study. Epidemiol Infect. 2025;154:e2. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41449806/"><span style="font-weight: 400;">41449806</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Abdulamir AS, Hafidh RR, Abu Bakar F. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011;30(1):11. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/21247505/"><span style="font-weight: 400;">21247505</span></a><span style="font-weight: 400;">.</span></p> <p> </p>
April 27, 2026
BC 077 – Comparaison des risques hémorragiques entre le rivaroxaban et l’apixaban dans le traitement de la maladie thromboembolique (étude COBRRA)
<p><span style="font-weight: 400;">Dans cette 77</span><span style="font-weight: 400;">e</span><span style="font-weight: 400;"> baladodiffusion, les Drs Alexandre Mutchmore et Geneviève LeTemplier discutent du traitement de l’embolie pulmonaire, en plus de réviser la littérature médicale de mars 2026.</span></p> <p> </p> <p><span style="font-weight: 400;">Quiz clinique (2 min 04), présentation principale (2 min 50), critique (21 min 43), retour sur le cas clinique (31 min 08), autres articles (33 min 45), réponse au quiz clinique (38 min 00).</span></p> <p> </p> <h2><b>Référence principale :</b></h2> <p> </p> <p><span style="font-weight: 400;">Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, et al; COBRRA Trial Investigators. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026;394(11):1051-1060. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41812192/"><span style="font-weight: 400;">41812192</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Articles associés : </b></h3> <p> </p> <p><span style="font-weight: 400;">Moores LK. The COBRRA Trial – Ending the Venous Thromboembolism Safety Toss-up. N Engl J Med. 2026;394(11):1123-1124. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41812199/"><span style="font-weight: 400;">41812199</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/21128814/"><span style="font-weight: 400;">21128814</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/23808982/"><span style="font-weight: 400;">23808982</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):2247-2259. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/34352279/"><span style="font-weight: 400;">34352279</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 ;4(19):4693-4738. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/33007077/"><span style="font-weight: 400;">33007077</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Autres articles d’intérêt récent : </b></h3> <p> </p> <p><span style="font-weight: 400;">Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, Jongs N, Mathieu C, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Brinker M, Scheerer MF, Russell J, Schloemer P, McGill JB; FINE-ONE Investigators. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026;394(10):947-957. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41780000/"><span style="font-weight: 400;">41780000</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, Li H, Birve F, Lihn AS, Perl S, Schlaich MP, Shibata H, Wang JG, Williams B; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988-999. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41794437/"><span style="font-weight: 400;">41794437</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Zhang Y, Liu Y, Li Y, Li Y, Gu X, Kang JH, Eliassen AH, Wang M, Rimm EB, Willett WC, Hu FB, Stampfer MJ, Wang DD. Coffee and Tea Intake, Dementia Risk, and Cognitive Function. JAMA. 2026;335(11):961-974. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41661604/"><span style="font-weight: 400;">41661604</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, Liu R, Zhao Y; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147-1160. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41765029/"><span style="font-weight: 400;">41765029</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Guides de pratique : </b></h3> <p> </p> <p><span style="font-weight: 400;">Bajaj JS, Jakab SS, Jesudian AB, Rahimi RS, Duarte-Rojo A, Chen PH, Wong RJ, Tapper EB, Tandon P. ACG Clinical Guideline: Hepatic Encephalopathy. Am J Gastroenterol. 2026;121(3):588-618. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41773757/"><span style="font-weight: 400;">41773757</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Creager MA, Barnes GD, Giri J, Mukherjee D, Jones WS, Burnett AE, Carman T, Casanegra AI, Castellucci LA, Clark SM, Cushman M, de Wit K, Eaves JM, Fang MC, Goldberg JB, Henkin S, Johnston-Cox H, Kadavath S, Kadian-Dodov D, Keeling WB, Klein AJP, Li J, McDaniel MC, Moores LK, Piazza G, Prenger KS, Pugliese SC, Ranade M, Rosovsky RP, Russo F, Secemsky EA, Sista AK, Tefera L, Weinberg I, Westafer LM, Young MN. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(12):e977-e1051. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41712677/"><span style="font-weight: 400;">41712677</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Référence du quiz clinique :</b></h3> <p> </p> <p><span style="font-weight: 400;">Abramson BL, Al-Omran M, Anand SS, Albalawi Z, Coutinho T, de Mestral C, et al. Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. Can J Cardiol. 2022;38(5):560-587. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/35537813/"><span style="font-weight: 400;">35537813</span></a><span style="font-weight: 400;">.</span></p>
March 20, 2026
BC 076 – Seuils de D-dimères ajustés en fonction de l’âge pour exclure une thrombose veineuse profonde (étude ADJUST-DVT)
<p><span style="font-weight: 400;">Dans cette 76</span><span style="font-weight: 400;">e</span><span style="font-weight: 400;"> baladodiffusion, les Drs Alexandre Mutchmore et Luc Lanthier discutent de diagnostic de la thrombose veineuse profonde, en plus de réviser la littérature médicale de janvier et février 2026.</span></p> <p> </p> <p><span style="font-weight: 400;">Quiz clinique (1 min 45), présentation principale (2 min 15), critique (23 min 10), retour sur le cas clinique (30 min 25), autres articles (31 min 48), réponse au quiz clinique (36 min 55).</span></p> <p> </p> <h2><b>Référence principale :</b></h2> <p> </p> <p><span style="font-weight: 400;">Le Gal G, Robert-Ebadi H, Thiruganasambandamoorthy V, Moustafa F, Penaloza A, Catella J, et al. Age-Adjusted D-Dimer Cutoff Levels to Rule Out Deep Vein Thrombosis. JAMA. 2026;335(5):416-24. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41490105/"><span style="font-weight: 400;">41490105</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Articles associés : </b></h3> <p> </p> <p><span style="font-weight: 400;">Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-24. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/24643601/"><span style="font-weight: 400;">24643601</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Ujueta F, Piazza G. Like a Fine Wine-Aging the D-Dimer to Improve Value and Clinical Efficiency. JAMA. 2026;335(5):403-4. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41490683/"><span style="font-weight: 400;">41490683</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Lim W, Le Gal G, Bates SM, Righini M, Haramati LB, Lang E, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-56. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/30482764/"><span style="font-weight: 400;">30482764</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><a href="https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=DEEPVEINTHROMBOSISDIAGNOSIS"><span style="font-weight: 400;">https://thrombosiscanada.ca/hcp/practice/clinical_guides?language=en-ca&guideID=DEEPVEINTHROMBOSISDIAGNOSIS</span></a></p> <p> </p> <p><a href="https://acforum.org/web/resource_files/1772710804-36404.pdf"><span style="font-weight: 400;">https://acforum.org/web/resource_files/1772710804-36404.pdf</span></a></p> <p> </p> <h3><b>Autres articles d’intérêt récent : </b></h3> <p> </p> <p><span style="font-weight: 400;">Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128-37. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41201837/"><span style="font-weight: 400;">41201837</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Verma A, Birnie DH, Jiang C, Heidbuchel H, Hindricks G, Kirchhof P, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. 2026;394(4):323-32. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41211931/"><span style="font-weight: 400;">41211931</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Wong CX, Cheung CC, Montenegro G, Oo HH, Pena IJ, Tang JJ, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. JAMA. 2026;335(4):317-25. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41206802/"><span style="font-weight: 400;">41206802.</span></a></p> <p> </p> <p><span style="font-weight: 400;">Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429-41. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41211918/"><span style="font-weight: 400;">41211918.</span></a></p> <p> </p> <p><span style="font-weight: 400;">Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529-39. </span></p> <p> </p> <p><span style="font-weight: 400;">Lee SJ, Yu HT, Lee YJ, Lee SH, Heo JH, Ahn SG, et al. Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. N Engl J Med. 2026;394(7):658-68. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41211917/"><span style="font-weight: 400;">41211917</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Rana AI, Zheng L, Castillo-Mancilla J, Bao Y, Sieczkarski S, Brooks KM, et al. Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges. N Engl J Med. 2026;394(9):858-71. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41707171/"><span style="font-weight: 400;">41707171</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Guides de pratique : </b></h3> <p> </p> <p><span style="font-weight: 400;">American Diabetes Association Professional Practice Committee for D. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41358896/"><span style="font-weight: 400;">41358896</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Andrade JG, Joza J, Chew DS, Ayala-Paredes F, Bennett MT, Essebag V, et al. The Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Selection, Implantation, and Management of Patients With Cardiac Implantable Electronic Devices. Can J Cardiol. 2026;42(1):1-68. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41539743/"><span style="font-weight: 400;">41539743</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Babitt JL, Berns JS, Bozkurt B, Cheung Khedairy RS, Cuevas Y, Effa EE, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/41485807/"><span style="font-weight: 400;">41485807</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S, et al. Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Am J Gastroenterol. 2026;121(1):31-79. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40862489/"><span style="font-weight: 400;">40862489</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <h3><b>Références du quiz clinique :</b></h3> <p> </p> <p><span style="font-weight: 400;">Sconfienza E, Tetti M, Forestiero V, Veglio F, Mulatero P, Monticone S. Prevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023;108(7):1813-1823. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/36718682/"><span style="font-weight: 400;">36718682</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1-G42. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/37318239/"><span style="font-weight: 400;">37318239</span></a><span style="font-weight: 400;">.</span></p> <p> </p> <p><span style="font-weight: 400;">Kebebew E. Adrenal Incidentaloma. N Engl J Med. 2021;384(16):1542-1551. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/33882207/"><span style="font-weight: 400;">33882207</span></a><span style="font-weight: 400;">.</span></p>
68 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Sans Filtre Podcast
Studio SF
Pharmascope
Pharmascope
Tout le monde s'haït
Marylène Gendron & Sam Cyr
La Tournée
Mathieu Sergerie
Sexe Oral
Lysandre Nadeau, Joanie Grenier
Mike Ward Sous Écoute
Mike Ward
La vie sociale
La vie sociale
On s'connait pas tant que ça
Studio SF
TRAIT PHARMACIEN
A.P.E.S.
Ouvre ton jeu avec Marie-Claude Barrette
Umano Productions
Finance 360 avec Alex Demers
Alexandre Demers
Core IM | Internal Medicine Podcast
Core IM Team
Investi
Bristol Media
Couple Ouvert
Thomas Levac et Stéphanie Vandelac
Finances Fondamentales
Finances Fondamentales
Deep-dive analytics for BaladoCritique - club de lecture médical
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is BaladoCritique - club de lecture médical?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.